TRUONG T, T., W. SAUTER, J. MCKAY, H. HOSGOOD, C. GALLAGHER, Ch. AMOS, M. SPITZ, J. MUSCAT, P. LAZARUS, T. ILLIG, H. WICHMANN, H. BICKEBOELLER, A. RISCH, H. DIENEMANN, Zuo-Feng ZHANG, B. NAEIM, P. YANG, S. ZIENOLDDINY, A. HAUGEN, L. LE MARCHAND, Yun-Chul HONG, J. KIM, E. DUELL, A. ANDREW, Ch. KIYOHARA, H. SHEN, K. MATSUO, T. SUZUKI, A. SEOW, D. NG, Q. LAN, D. ZARIDZE, N. SZESZENIA-DABROWSKA, J. LISSOWSKA, P. RUDNAI, E. FABIANOVA, V. CONSTANTINESCU, V. BENCKO, Lenka FORETOVÁ, V. JANOUT, N. CAPORASO, D. ALBANES, M. THUN, M. LANDI, J. TRUBICKA, M. LENER, J. LUBINSKI, Y. WANG, A. CHABRIER, P. BOFFETTA, P. BRENNAN and R. HUNG. International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis. Oxford: Oxford University Press, 2010, vol. 31, No 4, p. 625-633. ISSN 0143-3334. Available from: https://dx.doi.org/10.1093/carcin/bgq001.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants.
Authors TRUONG T, T. (250 France), W. SAUTER (276 Germany), J. MCKAY (250 France), H. HOSGOOD (840 United States of America), C. GALLAGHER (840 United States of America), Ch. AMOS (840 United States of America), M. SPITZ (840 United States of America), J. MUSCAT (840 United States of America), P. LAZARUS (840 United States of America), T. ILLIG (276 Germany), H. WICHMANN (276 Germany), H. BICKEBOELLER (276 Germany), A. RISCH (276 Germany), H. DIENEMANN (276 Germany), Zuo-Feng ZHANG (840 United States of America), B. NAEIM (840 United States of America), P. YANG (840 United States of America), S. ZIENOLDDINY (578 Norway), A. HAUGEN (578 Norway), L. LE MARCHAND (840 United States of America), Yun-Chul HONG (410 Republic of Korea), J. KIM (410 Republic of Korea), E. DUELL (250 France), A. ANDREW (840 United States of America), Ch. KIYOHARA (392 Japan), H. SHEN (156 China), K. MATSUO (392 Japan), T. SUZUKI (392 Japan), A. SEOW (702 Singapore), D. NG (702 Singapore), Q. LAN (840 United States of America), D. ZARIDZE (643 Russian Federation), N. SZESZENIA-DABROWSKA (616 Poland), J. LISSOWSKA (616 Poland), P. RUDNAI (348 Hungary), E. FABIANOVA (703 Slovakia), V. CONSTANTINESCU (642 Romania), V. BENCKO (203 Czech Republic), Lenka FORETOVÁ (203 Czech Republic, belonging to the institution), V. JANOUT (203 Czech Republic), N. CAPORASO (840 United States of America), D. ALBANES (840 United States of America), M. THUN (840 United States of America), M. LANDI (840 United States of America), J. TRUBICKA (616 Poland), M. LENER (616 Poland), J. LUBINSKI (616 Poland), Y. WANG (124 Canada), A. CHABRIER (250 France), P. BOFFETTA (250 France), P. BRENNAN (250 France, guarantor) and R. HUNG (250 France).
Edition Carcinogenesis, Oxford, Oxford University Press, 2010, 0143-3334.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 5.402
RIV identification code RIV/00216224:14110/10:00051822
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1093/carcin/bgq001
UT WoS 000276285200012
Keywords in English METHYLENE-TETRAHYDROFOLATE REDUCTASE; GENE POLYMORPHISMS; METHYLENETETRAHYDROFOLATE REDUCTASE; CHINESE POPULATION; SEQUENCE VARIANTS; INCREASED RISK; CENTRAL-EUROPE; DNA-REPAIR; XUAN-WEI; CELL
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 17/4/2012 10:07.
Abstract
Analysis of candidate genes in individual studies has had only limited success in identifying particular gene variants that are conclusively associated with lung cancer risk. In the International Lung Cancer Consortium (ILCCO), we conducted a coordinated genotyping study of 10 common variants selected because of their prior evidence of an association with lung cancer. These variants belonged to candidate genes from different cancer-related pathways including inflammation (IL1B), folate metabolism (MTHFR), regulatory function (AKAP9 and CAMKK1), cell adhesion (SEZL6) and apoptosis (FAS, FASL, TP53, TP53BP1 and BAT3). Methods. Genotype data from 15 ILCCO case-control studies were available for a total of 8431 lung cancer cases and 11 072 controls of European descent and Asian ethnic groups. Unconditional logistic regression was used to model the association between each variant and lung cancer risk. Results. Only the association between a non-synonymous variant of TP53BP1 (rs560191) and lung cancer risk was significant (OR = 0.91, P = 0.002). This association was more striking for squamous cell carcinoma (OR = 0.86, P = 6 x 10(-4)). No heterogeneity by center, ethnicity, smoking status, age group or sex was observed. In order to confirm this association, we included results for this variant from a set of independent studies (9966 cases/11 722 controls) and we reported similar results. When combining all these studies together, we reported an overall OR = 0.93 (0.89-0.97) (P = 0.001). This association was significant only for squamous cell carcinoma [OR = 0.89 (0.85-0.95), P = 1 x 10(-4)]. Conclusion. This study suggests that rs560191 is associated to lung cancer risk and further highlights the value of consortia in replicating or refuting published genetic associations.
PrintDisplayed: 28/5/2024 17:14